2006 Issues

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Wisconsin School of Medicine and Public Health and MDG Development Group. The University of Wisconsin School of Medicine and Public Health is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Wisconsin School of Medicine and Public Health designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Click here to download the CME post-test and program evaluation.

Need

Physicians in practice do not routinely scan journals for information that will enhance their ability to treat the various digestive disease states that they see regularly in their practices. With the growth of evidence-based medicine, there is a belief that there must be a more efficient means of keeping up on the ever-changing medical literature. IBD Watch provides a concise easy-to-read summary of the literature and key scientific presentations in a format that has been widely accepted by practicing physicians. Physicians who regularly read the monthly and special issues will gain increased exposure to emerging clinical data that can optimize treatment strategies resulting in improved patient responses and clinical outcomes.

Learning Objectives

At the conclusion of this activity, participants should be able to:

	Improve the quality of care for IBD patients through practice of evidence based medicine
	Be better informed about emerging diagnostic tools and treatment trends in inflammatory bowel disease
	Optimize treatment strategies resulting in improved patient responses and clinical outcomes

Intended Audience

IBD Watch is produced for physicians who diagnose or treat inflammatory bowel disease

There are no prerequisites for participating in this activity

Policy on Faculty and Sponsor Disclosure

As a provider accredited by the ACCME, it is the policy of the University of Wisconsin School of Medicine and Public Health to require the disclosure of the existence of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in the program. Detailed disclosure information is as follows.

Acknowledgment

The University of Wisconsin School of Medicine and Public Health and MDG Development Group gratefully acknowledge the independent educational grant provided by Abbott Laboratories, Centocor Inc., and Otsuka America Pharmaceuticals, Inc.

Course Instructions

In order to obtain credit the participant will need to circle the letter that represents the correct answer on the answer form. He/She must answer 70% of the questions correctly in order to receive credit.

Course Format

The participant should first read all 2006 newsletters including the 2 special editions, then complete and submit the post-test/evaluation. This entire process should take the participant 2 hours to complete.

Hardware and Software Requirements

In order to participate in this activity, an Internet connection, the Microsoft Internet Explorer web browser and Adobe Acrobat Reader® are required.

Release Date: 12/1/06

Expiration Date: 12/31/07

CME Disclosure

The faculty and joint sponsor reported the following:

Frank Fila, CEO, MDG Development Group, Managing Editor, IBD Watch

MDG Development Group has a client/provider relationship with Abbott Laboratories, Centocor Inc. and Otsuka American Pharmaceutical, Inc.

Stephen Hanauer, MD

	Indicates that he may reference unlabeled/unapproved uses of drugs in his presentations
	Indicates he has financial relationship(s) with commercial interest(s) as outlined below.
	He has received honoraria and was a consultant for Abbott Laboratories.
	He has received honoraria, was a consultant and speaker for Centocor Inc., Proctor & Gamble Pharmaceuticals, Inc., Shire Pharmaceuticals, Salix Pharmaceuticals Inc., and Prometheus Laboratories, Inc.

Sunanda Kane, MD

	Indicates that she may reference unlabeled/unapproved uses of drugs in her presentations
	Indicates she has financial relationship(s) with commercial interest(s) as outlined below.
	She has been a consultant for Centocor, Inc., Shire Pharmaceuticals and UCB Pharma, Inc.
	She has received honoraria from Centocor, Inc., Proctor & Gamble Pharmaceuticals and Shire Pharmaceuticals and UCB Pharma, Inc.
	She has received grants/research support and was a speaker for Proctor & Gamble Pharmaceuticals, Inc.
	She has been on a speakers bureau for Centocor, Inc., Proctor & Gamble Pharmaceuticals and Shire Pharmaceuticals.

Gary Roth Lichtenstein, MD

	Intends to reference unlabeled/unapproved uses of drugs or products in his presentation(s).
	Indicates he has financial relationship(s) with commercial interest(s) as outlined below.
	He has been a consultant for Abbott Laboratories, Astra-Zenecca, Inc., Axcan Corporation, Bristol-Myers Squibb Company, Centocor, Inc., Elan Pharmaceuticals, Gilead Sciences, Inc., Human Genome Sciences, Inc., Proctor & Gamble Pharmaceuticals, Inc., Prometheus Laboratories, Inc., Protein Design Laboratories Biopharma, Inc., Protomed Scientific, Salix Pharmaceuticals Inc., Schering Corporation, Serono, Inc., Shire Pharmaceuticals, GLAXOSMITHKLINE, Solvay Pharmaceuticals, Synta Pharmaceuticals, UCB Pharma, Inc. and Wyeth Pharmaceuticals.
	He had received grants/research support from Abbott Laboratories, Berlex, Inc., Centocor, Inc., Human Genome Sciences, Inc., Intesco Corporation, ISIS Corporation, Millenium Pharmaceuticals, Inc., Otsuka American Pharmaceutical, Inc., Protein Design Laboratories Biopharma, Inc., Protomed Scientific and Salix Pharmaceuticals, Inc.
	He has been on the speakers bureau for Astra-Zenecca, Inc., Axcan Corporation, Centocor, Inc., Proctor & Gamble Pharmaceuticals, Inc., Salix Pharmaceuticals Inc., Schering Corporation, Shire Pharmaceuticals and Solvay Pharmaceuticals.
	He has received honorarium from Falk Pharmaceuticals.

Daniel H. Present, MD

	Indicates that he may reference unlabeled/unapproved uses of drugs in his presentations
	Indicates he has financial relationship(s) with commercial interest(s) as outlined below.
	He has received grants/research support or was a consultant for Abbott Laboratories, Celltech Pharmaceuticals, Inc., Centocor Inc., CCFA, Elan Pharmaceuticals, Fulcrum Pharmaceuticals, Inc., Human Genome Sciences, Inc., Mayo Clinic, Millenium Pharmaceuticals, Inc., NIH (University of Pennsylvania), Otsuka American Pharmaceuticals, Inc., Presutti Laboratories, Proctor & Gamble Pharmaceuticals, Inc., Salix Pharmaceuticals Inc., Tech Lab, Teva Pharmaceuticals Industries, Ltd., UCB Pharma Inc. and ZymoGenetics, Inc.
	He is on the speaker’s bureau for Axcan Pharma Inc., Proctor & Gamble Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Shire Pharmaceuticals and TAP Pharmaceutical Products, Inc.

Bruce E. Sands, MD, MS

	Indicates that he may reference unlabeled/unapproved uses of drugs in his presentations
	Indicates he has financial relationship(s) with commercial interest(s) as outlined below.
	He has been a consultant for received grants/research support from Abbott Laboratories, Biogen IDEC, Elan Pharmaceuticals, Otsuka American Pharmaceuticals, Prometheus Laboratories, Inc., Protein Design Laboratories Biopharma, Inc., Synta Pharmaceuticals Corp. and Wyeth Pharmaceuticals
	He has been a consultant, received grants/research and given lectures for Berlex Inc., Centocor Inc. and Proctor & Gamble Pharmaceuticals, Inc.
	He has received consultant fees and given lectures for Shire Pharmaceuticals and Solvay Pharmaceuticals
	He has received consultant fees and research support from Serono, Inc.

John B. Wyman, MD, Educational Reviewer

	Indicates that he may reference unlabeled/unapproved uses of drugs in his presentations
	Indicates that he has received consultant fees and given lectures for Novartis Pharmaceuticals

Rita Carrier, Medical Writer

Indicates that she receives writer's fees from MDG Development Group; she has no other relationships with other commercial interests to disclose

NOTICE

The University of Wisconsin School of Medicine and Public Health advises the participant that one or more presentations in this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.

Jointly sponsored by and

IBD Watch®

IBD Watch^®